Oncology Final Exam
Name therapeutic agent to treat EGFR mutation biomarker in
nonsmall-cell lung cancer.Hint: 3 major ones. correct answers1.
Gefitinib
2. Erlotinib
3. Afatinib
Name therapeutic agent to treat ALK positive biomarker(EML4-ALK
rearrangement) for NSCLC OR ROS1 biomarker. correct answersCrizotinib
Name therapeutic agents to treat BRAF positive biomarker for
NSCLC. correct answersVemurafenib and dabraenib
HER2 overexpression is associated with better or worse prognosis for
breast cancer? correct answersWorse prognosis.
HER-2 testing includes and (name two
tests). These tests detect . HER2 positive breast cancer may be
treated with
. correct answers1. FISH and IHC(immunohistochemistry)
4. HER 2 protein overexpression and gene amplification from the tumor
5. Trastuzumab
HER2 is evaluated at these two times in a breast cancer patient's course
of therapy. correct answersDiagnosis or recurrence.
Oncotoype Dx Test- explain the test, how it's scored, when it's indicated.
correct answers1. A 21 gene expression test(not genotype) on breast tumor
tissue. Expression is measured from multiple genes involving cancer cell
proliferation, invasion, estrogen, and HER2 genes.
6.Measured from 0-100 on recurrence score obtained from expression
test performed on tumor. This number corresponds to likelihood of
recurrence w/in 10 yrs.
7. Use in newly diagnosed ER +, Node - or +, HER-2 negative breast cancer
What is considered low risk, Intermediate risk, or high risk RS oncotype dx
score? What therapy for each risk category to recommend in ER/PR+ breast
cancer? correct answersLow= 0-18%, little to no chemo benefit(most women
fall in this category).
Recommend only tamoxifen.
Intermediate= 18-31%, may be a chemo benefit. May or may not use
combo adjuvant chemo followed by tamoxifen.
High= 31% and above, Large chemo benefit. Combination adjuvant chemo
followed by tamoxifen.
How is Mammaprint testing different from OncotypeDx? 4
differences. correct answers1. No % score, just says high or low risk
Name therapeutic agent to treat EGFR mutation biomarker in
nonsmall-cell lung cancer.Hint: 3 major ones. correct answers1.
Gefitinib
2. Erlotinib
3. Afatinib
Name therapeutic agent to treat ALK positive biomarker(EML4-ALK
rearrangement) for NSCLC OR ROS1 biomarker. correct answersCrizotinib
Name therapeutic agents to treat BRAF positive biomarker for
NSCLC. correct answersVemurafenib and dabraenib
HER2 overexpression is associated with better or worse prognosis for
breast cancer? correct answersWorse prognosis.
HER-2 testing includes and (name two
tests). These tests detect . HER2 positive breast cancer may be
treated with
. correct answers1. FISH and IHC(immunohistochemistry)
4. HER 2 protein overexpression and gene amplification from the tumor
5. Trastuzumab
HER2 is evaluated at these two times in a breast cancer patient's course
of therapy. correct answersDiagnosis or recurrence.
Oncotoype Dx Test- explain the test, how it's scored, when it's indicated.
correct answers1. A 21 gene expression test(not genotype) on breast tumor
tissue. Expression is measured from multiple genes involving cancer cell
proliferation, invasion, estrogen, and HER2 genes.
6.Measured from 0-100 on recurrence score obtained from expression
test performed on tumor. This number corresponds to likelihood of
recurrence w/in 10 yrs.
7. Use in newly diagnosed ER +, Node - or +, HER-2 negative breast cancer
What is considered low risk, Intermediate risk, or high risk RS oncotype dx
score? What therapy for each risk category to recommend in ER/PR+ breast
cancer? correct answersLow= 0-18%, little to no chemo benefit(most women
fall in this category).
Recommend only tamoxifen.
Intermediate= 18-31%, may be a chemo benefit. May or may not use
combo adjuvant chemo followed by tamoxifen.
High= 31% and above, Large chemo benefit. Combination adjuvant chemo
followed by tamoxifen.
How is Mammaprint testing different from OncotypeDx? 4
differences. correct answers1. No % score, just says high or low risk
